CONTEXT: It seems that having Real-World Data (capitalised for emphasis) alongside your traditional clinical data at a poster presentation now adds weight to the overall message. RWR is the must-have accessory this conference season.
IMPACT: Medium
READ TIME: 3 mins
Quality Level Mean [1 – 10]: 7
1. “Retrospective Analyses Evaluate Efficacy of Quarterly and Monthly AJOVY Doses and Changes in Acute Medication Use. A retrospective, panel-based review of 1,003 patient charts from 421 physicians examined the effectiveness of quarterly and monthly doses of fremanezumab for reducing monthly migraine days and monthly headache days in adult migraine patients over a six-month time period.”
2. “The data being presented at the meeting span 17 posters and include post-hoc Phase 3 data examining the long-term response of AJOVY in patients who initially did not respond to treatment, an analysis of real-world treatment patterns for patients prescribed AJOVY, and a retrospective evaluation of quarterly and monthly dosing with AJOVY in a real-world setting.”
3. “AJOVY is the first and only long-acting anti-CGRP subcutaneous injection approved in the US for the preventive treatment of migraine in adults that offers both quarterly and monthly dosing options.1+±. Post Hoc Analysis Examines Long-Term Efficacy of AJOVY in Patients Who Initially Responded Inadequately. Patients who completed the Phase 3 HALO Episodic Migraine (EM) and Chronic Migraine (CM) clinical trial, along with new patients, entered the HALO long-term study.”
4. “These posters, US Real-world Effectiveness of Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in Adult Patients with Migraine, and US Real-World Patient Characteristics, Acute Medication Use, and Treatment Patterns for Patients Initiating Fremanezumab, are posters P10.031 and P10.088, respectively, in the online program.”
5. “Retrospective Review Evaluates Real-World Adherence, Persistence, Switching, and Reinitiation by Quarterly and Monthly Dosing Regimen in Patients Prescribed AJOVY in US Physician Practices. A retrospective review of real-world data obtained from the Veradigm Health Insights Database examined treatment adherence and persistence for patients prescribed quarterly versus monthly dosing.”